cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Uniqure Nv
9 own
14 watching
Current Price
$4.65
$-0.07
(-1.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
976.47M
52-Week High
52-Week High
21.00000
52-Week Low
52-Week Low
4.25000
Average Volume
Average Volume
0.67M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
5.0703
iconMarket Capitalization976.47M
icon52-Week High21.00000
icon52-Week Low4.25000
iconAverage Volume0.67M
iconDividend Yield--
iconP/E Ratio5.0703
What does the Uniqure Nv do?
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More
How much money does Uniqure Nv make?
News & Events about Uniqure Nv.
Business Wire
11 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or...
Business Wire
11 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or...
PR Newswire
11 months ago
Thinking about buying stock in bluebird bio, Uniqure, Terawulf, Metaworks Platforms, or Nikola Corp? Thinking about buying stock in bluebird bio, Uniqure, Terawulf, Metaworks Platforms, or Nikola Corp? PR Newswire NEW YORK, June 21, 2023 NEW YORK, June 21, 2023 /PRNewswire/ -- InvestorsObserver...
PR Newswire
11 months ago
Thinking about buying stock in Eightco Holdings, Uniqure, Atento, Red Cat Holdings, or Opendoor Technologies? Thinking about buying stock in Eightco Holdings, Uniqure, Atento, Red Cat Holdings, or Opendoor Technologies? PR Newswire NEW YORK, June 21, 2023 NEW YORK, June 21, 2023 /PRNewswire...
Globe Newswire
11 months ago
LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to Jeannette Potts, the Companys newly hired ...
Frequently Asked Questions
Frequently Asked Questions
What is Uniqure Nv share price today?
plus_minus_icon
Can Indians buy Uniqure Nv shares?
plus_minus_icon
How can I buy Uniqure Nv shares from India?
plus_minus_icon
Can Fractional shares of Uniqure Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Uniqure Nv stocks?
plus_minus_icon
What is today’s traded volume of Uniqure Nv?
plus_minus_icon
What is today’s market capitalisation of Uniqure Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Uniqure Nv?
plus_minus_icon
What percentage is Uniqure Nv down from its 52-Week High?
plus_minus_icon
What percentage is Uniqure Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$4.65
$-0.07
(-1.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00